Venture Certified
| 기술평가보증기업(기금) | 2009-08-24 ~ 2011-08-23 | 20090107651 | 2009-08-24 |
| 벤처투자유형 | 2011-08-24 ~ 2013-08-23 | 20110300189 | 2009-08-24 |
| 벤처투자유형 | 2013-08-24 ~ 2015-08-23 | 20130300194 | 2009-08-24 |
| 벤처투자유형 | 2015-08-24 ~ 2017-08-23 | 20150300299 | 2009-08-24 |
| 벤처투자유형 | 2017-08-24 ~ 2019-08-23 | 20170300402 | 2009-08-24 |
| 연구개발유형 | 2019-08-24 ~ 2021-08-23 | 20190108002 | 2009-08-24 |
| 연구개발유형 | 2021-08-24 ~ 2024-08-23 | 20210721020066 | 2009-08-24 |
| 연구개발유형 | 2024-08-24 ~ 2027-08-23 | 20240821020004 | 2009-08-24 |
Revenue CAGR +226.0%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 930B | 835B | 87B |
| Operating Profit | 306B | -9.0B | -215B |
| Net Profit | 471B | 49B | 21B |
| Total Assets | 3,316B | 2,039B | 1,858B |
| Total Liabilities | 305B | 174B | 86B |
| Total Equity | 3,011B | 1,865B | 1,773B |
▲ 101.6%
▲ 373.8%
▲ 126.7%
▲ 42.9%
▲ 722.3%
| Name | Position | Role |
|---|---|---|
| 전태연 | 대표이사 | 대표 |
| Patent Title | Applicant | Application No. | Filing Date | Status |
|---|---|---|---|---|
| 신규한 항-Ang-2 항체 및 이의 용도 | 주식회사 알테오젠바이오로직스 | 1020250023946 | 2025-02-24 | 공개 |
| 재조합 히알루로니다제의 생산 방법 | (주)알테오젠 | 1020240170525 | 2024-11-26 | 공개 |
| N-말단 및/또는 C-말단이 절단된 가용성 PH20 폴리펩티드 및 이의 용도 | (주)알테오젠 | 1020240087254 | 2024-07-03 | ��개 |
| 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 | (주)알테오젠 | 1020257031675 | 2024-03-21 | 공개 |
| 재조합 히알루로니다제의 생산 방법 | (주)알테오젠 | 1020240036308 | 2024-03-15 | 등록 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "대전광역시 유성구",
"ceo_name": "전태연",
"certificate": [
{
"cert_number": "20090107651",
"changes": "",
"disclosure_date": "2009-08-24",
"first_cert_date": "2009-08-24",
"no": "1",
"type": "기술평가보증기업(기금)",
"valid_period": "2009-08-24 ~ 2011-08-23"
},
{
"cert_number": "20110300189",
"changes": "",
"disclosure_date": "2011-08-25",
"first_cert_date": "2009-08-24",
"no": "2",
"type": "벤처투자유형",
"valid_period": "2011-08-24 ~ 2013-08-23"
},
{
"cert_number": "20130300194",
"changes": "",
"disclosure_date": "2013-07-18",
"first_cert_date": "2009-08-24",
"no": "3",
"type": "벤처투자유형",
"valid_period": "2013-08-24 ~ 2015-08-23"
},
{
"cert_number": "20150300299",
"changes": "",
"disclosure_date": "2015-07-28",
"first_cert_date": "2009-08-24",
"no": "4",
"type": "벤처투자유형",
"valid_period": "2015-08-24 ~ 2017-08-23"
},
{
"cert_number": "20170300402",
"changes": "",
"disclosure_date": "2017-07-20",
"first_cert_date": "2009-08-24",
"no": "5",
"type": "벤처투자유형",
"valid_period": "2017-08-24 ~ 2019-08-23"
},
{
"cert_number": "20190108002",
"changes": "",
"disclosure_date": "2019-07-10",
"first_cert_date": "2009-08-24",
"no": "6",
"type": "연구개발유형",
"valid_period": "2019-08-24 ~ 2021-08-23"
},
{
"cert_number": "20210721020066",
"changes": "",
"disclosure_date": "2021-07-21",
"first_cert_date": "2009-08-24",
"no": "7",
"type": "연구개발유형",
"valid_period": "2021-08-24 ~ 2024-08-23"
},
{
"cert_number": "20240821020004",
"changes": "대표자",
"disclosure_date": "2024-08-21",
"first_cert_date": "2009-08-24",
"no": "8",
"type": "연구개발유형",
"valid_period": "2024-08-24 ~ 2027-08-23"
}
],
"company_name": "㈜알테오젠",
"corp_no": "160111-*******",
"financials": {
"2022": {
"capital_stock": 26207738000,
"cost_of_sales": 5493546000,
"current_assets": 111923741000,
"current_liabilities": 6754226000,
"gross_profit": 3256373000,
"net_income": 2114428000,
"net_income_bs": 2114428000,
"non_current_assets": 73920649000,
"non_current_liabilities": 1834447000,
"non_operating_expenses": 419748000,
"non_operating_income": 24005074000,
"operating_profit": -21470898000,
"revenue": 8749919000,
"sga_expenses": 24727271000,
"total_assets": 185844390000,
"total_equity": 177255717000,
"total_liabilities": 8588673000
},
"2023": {
"capital_stock": 26505914000,
"cost_of_sales": 51796660000,
"current_assets": 131162259000,
"current_liabilities": 15908592000,
"gross_profit": 31681716000,
"net_income": 4876840000,
"net_income_bs": 4870809000,
"non_current_assets": 72780589000,
"non_current_liabilities": 1506828000,
"non_operating_expenses": 1794573000,
"non_operating_income": 7575738000,
"operating_profit": -904325000,
"revenue": 83478376000,
"sga_expenses": 32586041000,
"total_assets": 203942848000,
"total_equity": 186527428000,
"total_liabilities": 17415420000
},
"2024": {
"capital_stock": 26659414000,
"cost_of_sales": 29452400000,
"current_assets": 181866457000,
"current_liabilities": 24926555000,
"gross_profit": 63516645000,
"net_income": 47141705000,
"net_income_bs": 71232721000,
"non_current_assets": 149781556000,
"non_current_liabilities": 5594527000,
"non_operating_expenses": 1460926000,
"non_operating_income": 17972800000,
"operating_profit": 30629831000,
"revenue": 92969045000,
"sga_expenses": 32886814000,
"total_assets": 331648013000,
"total_equity": 301126931000,
"total_liabilities": 30521082000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "9,999,990,000",
"changes": "9,999,990,000",
"date": "2016-09-07"
}
],
"main_products": "항체 바이오시밀러 및 바이오베터 의약품 연구개발",
"phone": "042-384-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| Employment Insurance | 2026-02-25 | Collected |
| G2B Procurement | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |